ArticleThe Journal of pediatrics2016
Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children.
Article in The Journal of pediatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Community-level interventions for mitigating the risk of waterborne diarrheal diseases: a systematic review.Systematic reviews · 2022Pooled it
- Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review and Meta-analysis.The Pediatric infectious disease journal · 2021Pooled it
- The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.Epidemiology (Cambridge, Mass.) · 2020Pooled it
- Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials.The Lancet. Infectious diseases · 2019Pooled it
- Efficacy of rotavirus vaccines in Indonesia: A review of genotype distribution and impact.Narra J · 2025Review
- Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.The Lancet. Global health · 2019Article
- Economic Evaluation of Human Rotavirus Vaccine in Thailand.Infectious diseases and therapy · 2019Article
- Case-Control Study of Rotavirus Vaccine Effectiveness Compared to Test-Negative Controls or Hospital Controls.Journal of epidemiology · 2019Article
- Effectiveness of the Oral Human Attenuated Rotavirus Vaccine: A Systematic Review and Meta-analysis-2006-2016.Open forum infectious diseases · 2018Review
- Rotavirus Vaccines and Health Care Utilization for Diarrhea in US Children, 2001 to 2015.The Pediatric infectious disease journal · 2018Article
- A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact.Expert review of vaccines · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveUsing case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent rotavirus vaccine (RV5) series given in infancy against rotavirus disease resulting in hospital emergency department or inpatient care. STUDY
designChildren were eligible for enrollment if they presented to any 1 of 3 hospitals in Atlanta, Georgia with diarrhea ≤10 days duration during January-June 2013 and were born after RV1 introduction. Stool samples were tested for rotavirus by enzyme immunoassay and immunization records were obtained from providers and the state electronic immunization information system. Case-subjects (children testing rotavirus antigen-positive) were compared with children testing rotavirus antigen-negative.
resultsOverall, 98 rotavirus-case subjects and 175 rotavirus-negative controls were enrolled. Genotype G12P[8] predominated (n = 87, 89%). The VE of 2 RV1 doses was 84% (95% CI 38, 96) among children aged 8-23 months and 82% (95% CI 41, 95) among children aged ≥24 months. For the same age groups, the VE of 3 RV5 doses was 80% (95% CI 27, 95) and 87% (95% CI 22, 98), respectively.
conclusionsUnder routine use, the RV1 and RV5 series were both effective against moderate-to-severe rotavirus disease during a G12P[8] season, and both vaccines demonstrated sustained protection beyond the first 2 years of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.